Fairvalue-Calculator Fairvalue-Calculator
EN DE

Amplia Therapeutics Limited (INNMF) Fair Value & Analysis

Healthcare · US · Market cap $41.1M

Price$0.0900
Fair Value$0.0540
Upside-40.0%
Quality95/100
Evidence: Low Range $0.0270 – $0.0720

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Amplia Therapeutics Limited (INNMF) currently trades at $0.0900, while our model-based Fair Value estimate is $0.0540 — implying the stock looks roughly 40.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Amplia Therapeutics Limited (INNMF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0540 versus a price of $0.0900 — about −40% (overvalued). Model-based estimate, not financial advice.
What is the fair value of INNMF?
Our 21-model fair value for Amplia Therapeutics Limited is $0.0540 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0900.
What is the quality score of INNMF?
Amplia Therapeutics Limited has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.